Supreme Court scrutiny of drug mark-ups puts hospital margins at risk
The Supreme Court questioned on 22 September why the 16% trade margin on scheduled drugs could not extend to non-scheduled drugs. JM Financial Institutional Securities estimates a 2-4% profit-margin hit for hospitals if capped. The next hearing is scheduled for 12 October.
Read the source at Mint · MarketsThe numbers
| Medicines share of hospital revenue: | 20-25% |
|---|
Why it matters to operators and investors
JM Financial estimates a potential 2–4% hit to hospital profit margins if drug trade margins are capped, making pharmacy dependence a key earnings risk with medicines contributing 20–25% of revenue.
What to watch next
- Directions issued at the 12 October hearing
- An order specifying the cap's coverage and implementation date
- Hospital disclosures of medicine revenue and profit margins
- Announced changes to hospital pharmacy prices or service charges
The counter-case
A binding cap on non-scheduled drug margins could compress hospital pharmacy profits, especially where medicines generate substantial earnings. Offsetting this through higher procedure or service charges may be difficult under insurer contracts and competitive pressure. However, judicial scrutiny alone does not establish that a cap will be imposed.